UCB's new meds spur sales growth; Otsuka nabs NICE backing for kidney med;

> Belgium's UCB hiked its full-year financial outlook on strong growth of three of its new drugs--Cimzia, Vimpat and Neupro--and ongoing sales of its off-patent epilepsy med Keppra. Report

> Otsuka's Jinarc, a treatment for autosomal dominant polycystic kidney disease, won backing from England's cost-effectiveness watchdogs. Report

> Merck & Co. ($MRK) said its price cut on Remicade in the U.K. will save England's National Health Service millions of pounds. Report

And Finally... More than three-fourths of Americans say the cost of prescription drugs for serious diseases is their chief health concern, a Kaiser Family Foundation poll found. Report

Suggested Articles

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.

W2O Group and California Life Sciences' new data-driven platform tracks top COVID-19 news and conversations in the life science industry.